ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Titan Pharmaceuticals, Inc. (TTNP) stock declined over -4.83%, trading at $3.55 on NASDAQ, down from the previous close of $3.73. The stock opened at $3.74, fluctuating between $3.55 and $3.70 in the recent session.
South San Francisco, CA 94080-1958
United States
Website: https://www.titanpharm.comContact: 650 244 4990Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.
Employees | 4 |
Beta | 1.28 |
Sales or Revenue | $184.00K |
5Y Sales Change% | -0.992% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |